Drug Trial Radar · NCT07498426
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jun 3, 2026
Primary completion
Jul 20, 2029
Study completion Jul 18, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 41 years, up to 81 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.
Conditions
- Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Interventions
NIO752Other
Solution of antisense oligonucleotide.
PlaceboDrug
Placebo solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the mPSPRS-10 scoreTime frame: Baseline, Week 72
Locations
64 sites in 12 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Scottsdale, Arizona · Recruiting
Univ of California San Francisco
San Francisco, California · Recruiting
CenExcel Rocky Mtn Clin Research
Englewood, Colorado · Recruiting
Parkinsons Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida · Recruiting
Mayo Jacksonville
Jacksonville, Florida · Recruiting
University of Kentucky - C201 Clinic
Lexington, Kentucky · Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Central TX Neuro Consultants P A
Round Rock, Texas · Recruiting
Novartis Investigative Site
Kogarah, New South Wales, Australia · Recruiting
Novartis Investigative Site
Westmead, New South Wales, Australia · Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia · Recruiting
Novartis Investigative Site
Bruges, Belgium · Recruiting
Novartis Investigative Site
Leuven, Vlaams Brabant, Belgium · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Jinan, China · Recruiting
Novartis Investigative Site
Shanghai, China · Recruiting
Novartis Investigative Site
Suzhou, China · Recruiting
Novartis Investigative Site
Wuhan, China · Recruiting
Novartis Investigative Site
Chengdu, Sichuan, China · Recruiting
Novartis Investigative Site
Caen, France · Recruiting
Novartis Investigative Site
Créteil, France · Recruiting
Novartis Investigative Site
Lille, France · Recruiting
Novartis Investigative Site
Marseille, France · Recruiting
Novartis Investigative Site
Nantes, France · Recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Rennes, France · Recruiting
Novartis Investigative Site
Toulouse, France · Recruiting
Novartis Investigative Site
Beelitz, Germany · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Stadtroda, Germany · Recruiting
Novartis Investigative Site
Tübingen, Germany · Recruiting
Klinik für Neurologie (Schwerpunkt Neurodegeneration)
Ulm, Germany · Recruiting
Novartis Investigative Site
Munich, Bavaria, Germany · Recruiting
Novartis Investigative Site
Würzburg, Bavaria, Germany · Recruiting
Novartis Investigative Site
Bonn, North Rhine-Westphalia, Germany · Recruiting
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, Germany · Recruiting
Novartis Investigative Site
Dresden, Saxony, Germany · Recruiting
Novartis Investigative Site
Leipzig, Saxony, Germany · Recruiting
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.